Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.
Sumitomo Corporation remains a 'Buy', as I see the expected uptrend in ROIC and ROE justifying a higher P/B multiple. Management targets a 100bps ROIC expansion over the next five years at the recent ...
Forbes contributors publish independent expert analyses and insights. I am the Kester and Brynes Professor at Columbia Business School and a Chazen Senior Scholar at the Jerome A. Chazen Institute for ...
Carnival Corporation & plc’s CCL latestearnings callhighlights a potential inflection point in its long-term profitability. Management reported return on invested capital (“ROIC”) above 13% in fiscal ...
Carnival Corporation & plc CCL is entering its next stage of operational recovery with a meaningfully stronger return profile, highlighted by return on invested capital (ROIC) reaching 13% in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results